Cocoa and Metabolic Health in Prediabetes

Prediabetes Clinical Trial

Official title:

Dietary Cocoa for Inhibition of Metabolic Endotoxemia and Glucose Intolerance

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02203240
• Other study ID #: VT13261005
• Status: Completed
• Phase: N/A
• Start date: June 2014
• Est. completion date: May 2016

Study information

• Verified date: September 2023
• Source: Virginia Polytechnic Institute and State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the impact of consuming cocoa on blood glucose levels, glucose metabolism, and other markers of pre-diabetes in overweight and/or obese individuals. Our hypothesis is that consumption of cocoa improves insulin sensitivity and glucose metabolism in subjects at risk for developing type-2 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: May 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Body Mass Index (BMI) greater than or equal to 25 and less than 40.

• Have at least one of the following: 1) impaired fasting glucose (IFG) after an overnight fast with plasma glucose concentration between 100-125 mg/dl, 2) impaired glucose tolerance (IGT) as identified by the standard Oral Glucose Tolerance Test (OGTT) with 2 hour plasma glucose concentration between 140-200 mg/dl following 75 g glucose OGTT, 3) HbA1c levels between 5.7-6.4% or 4) considered at risk to developing type 2 diabetes by the American Diabetes Association risk assessment. If subjects are above the prediabetic range for any of these tests (indicating they may be type 2 diabetic), they will be excluded and referred to their physician.

• Weight stable (+/-2 kg) for the last 6 months.

• Sedentary to recreationally active (less than 2 d/wk, 20 min/d).

• Have a blood pressure that is less than 160/100 mmHg, total cholesterol that is less than 300 mg/dl and a triglyceride concentration of less than 450 mg/dl.

Exclusion Criteria:

• Past or current history of coronary heart disease, stroke or major cardiovascular disease events, respiratory diseases, endocrine or metabolic diseases (including type 1 and type 2 diabetes), inflammatory bowel disease, cancer, or neurological or hematological disorders that would compromise the study or the health of the subject.

• Past or current history of gastrointestinal disorders (including lactose intolerance, ulcers, cancer (stomach, intestinal, colon, pancreatic, liver, etc) NASH, NAFLD, cirrhosis, IBD/IBS, celiac disease, etc).

• Current use of any medication including but not limited to cholesterol lowering medication (including fibric acid derivatives and niacin), antibiotics, immunosuppressive drugs, azole antifungals, non-steroidal anti-inflammatory drugs (NSAIDs), hormone replacement therapy or antioxidants/supplements.

• Use of antibiotics, prebiotics, or probiotics within the prior 3 months.

• Smoking or other tobacco use

• Habitual consumption of alcohol more than 2 servings/d for males and 1 serving/d for females.

• Strict vegetarians or vegans, or strong aversions to major food groups that may be part of the controlled diet.

• Recent surgery

• History of alcohol or drug abuse.

• Pregnant or plan to become pregnant

• Allergic to either lidocaine or bupivacaine

Related Conditions & MeSH terms

• Glucose Intolerance
• Prediabetes
• Prediabetic State

Intervention

Other:
• Cocoa

• Placebo

Locations

Country	Name	City	State
United States	Human Integrative Physiology Laboratory	Blacksburg	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
Virginia Polytechnic Institute and State University	The Hershey Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in insulin sensitivity	Insulin sensitivity will be determined using Bergman's minimal model (MINMOD Millennium software) via a frequently sampled intravenous glucose tolerance test (IVGTT). Fasting baseline blood samples will be taken prior to the dextrose injection (0.3 g/kg; 50% solution) at minute 0. Venous samples will be collected at minutes 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 18. Insulin (0.025 U/kg) will be injected at minute 20. Venous sampling will continue at minutes 22, 23, 24, 25, 27, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, and 180. Glucose concentration will be immediately analyzed an automated glucose oxidase analyzer. Insulin will be later measured from serum using the Immulite 1000 immunoassay analyzer.	Baseline and 4 weeks
Secondary	Change in blood glucose response to a mixed meal	The test meal will be 2-8 oz. servings of a meal replacement beverage providing a mixed macronutrient profile, supplemented with either a cocoa beverage dry mix (10 g cocoa) or a calorie-matched placebo beverage mix (0 g cocoa). Blood samples will be taken at baseline and subsequently 1, 2, 3, and 4 hours after the first sip of the test beverage. Plasma glucose concentrations will be analyzed immediately using a glucose auto-analyzer (Yellow Springs Instruments).	Baseline and 1 week
Secondary	Change in hormone secretion response to a mixed meal	Serum insulin, GLP-1, GIP, and C-peptide concentrations will be determined using commercially available enzyme-linked immunosorbent assay (ELISA) kits from the blood samples drawn at baseline, 1, 2, 3, and 4 hours during the mixed meal challenge.	Baseline and 1 week
Secondary	Change in skeletal muscle metabolic flexibility	Subjects will consume a high fat meal containing 820 kcal; 52 g total carbohydrates, 24 g protein, and 58 g fat. During the high fat challenge session, two skeletal muscle biopsies will be conducted on alternate legs; one before the high fat meal and one 4 hours later. Biopsies of the vastus lateralis will be performed using a 5 mm modified Bergström needle. Collected tissue will be washed in 0.9% sterile saline to remove blood and tissue. Samples will be weighed and added to buffer and placed on ice for immediate analysis of substrate flexibility. For substrate flexibility, pyruvate oxidation will be used to assess the activity of pyruvate dehydrogenase. Calculated metabolic flexibility is expressed as a ratio of pyruvate oxidation to pyruvate oxidation + free fatty acids.	Baseline and 4 weeks
Secondary	Change in blood endotoxin levels	During the high fat challenge (see Outcome 4), blood samples will be collected at baseline and 1, 2, 3, and 4 h after the first bite of the meal. Serum endotoxin will be measured in duplicate using Limulus Amebocyte Lysate Pyrogent ® 5000 assay kits.	Baseline and 4 weeks
Secondary	Change in gut permeability	The four-sugar [40 g sucrose, 1 g mannitol, 1 g sucralose and 5 g lactulose] probe test will be used to assess total gut permeability. After an overnight fast and urine evacuation, participants will be asked to consume the sugar-probe beverage within 5 minutes. They will be given two breakfast sandwiches to consume immediately. Participants will be instructed to collect all of their urine in a provided container from the time the beverage was consumed (0 h) until 5 h. A second urine collection container will be filled between 6-24 h. Twenty-four hours later, the volume of urine in each container will be measured and aliquots collected for later analysis. Gastroduodenal permeability is defined as sucrose/mannitol ratio (0-5 h). Small intestinal permeability is defined as the calculated lactulose/mannitol ratio for 0-5 samples. Colonic permeability is defined as both the 6-24 h lactulose/mannitol ratio and 6-24 h sucralose/mannitol ratio.	Baseline and 4 weeks